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As the global COVID-19 pandemic advances, it increasingly impacts those vulnerable populations 
who already bear a heavy burden of neglected tropical disease. Chagas disease (CD), a neglected 
parasitic infection, is of particular concern because of its potential to cause cardiac, gastro-
intestinal, and other complications which could increase susceptibility to COVID-19. The over 
one million people worldwide with chronic Chagas cardiomyopathy require special consideration 
because of COVID-19’s potential impact on the heart, yet the pandemic also affects treatment 
provision to people with acute or chronic indeterminate CD. In this document, a follow-up to 
the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and 
Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we pro-
vide preliminary guidance for testing, treatment, and management of patients affected by both 
diseases, while highlighting emerging healthcare access challenges and future research needs.
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Introduction
In 2020, the SARS-CoV-2 virus, which causes COVID-19, took the world by storm. The biological and social 
implications of this global pandemic may not be fully understood for years. However, what is increasingly 
clear is that like other diseases, COVID-19 disproportionately affects those living at the social margins, while 
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also being particularly severe in older individuals and those with certain underlying health conditions. These 
are both key considerations as COVID-19 increasingly intersects with the world’s neglected diseases, includ-
ing Chagas disease (CD), a multi-systemic disorder caused by Trypanosoma cruzi (T. cruzi) that can affect the 
cardiovascular, digestive and central nervous systems [1]. CD is endemic in much of Latin America, which is 
increasingly bearing the brunt of the pandemic. The first reported Latin American case of COVID-19 was on 
February 26, 2020 in Brazil; by September 4th, there were over 7.5 million confirmed infections and over 
280,000 deaths in the region [2], with numbers still increasing rapidly at the time of writing this paper. 
Several aspects of CD are of particular concern in light of what we know about COVID-19: Many people liv-
ing with CD are socioeconomically vulnerable and have limited access to healthcare, the vast majority are 
undiagnosed, most are aging, and over a million have already progressed to a cardiac form of the disease 
[3, 4]. This paper will focus on the potential interactions between CD and COVID-19 in coinfected indi-
viduals, which become increasingly important as the pandemic spreads rapidly through Latin American 
countries where CD is endemic.
On March 30, 2020 the Inter-American Society of Cardiology and the World Heart Federation published 
a roadmap that provides a comprehensive overview of CD, with steps for improving healthcare access [5]. 
Also in March of 2020, the Chagas Coalition prepared a question and answer document with information 
about COVID-19 for people with CD.1 In April 2020, the Drugs for Neglected Diseases initiative’s Chagas 
Research Platform reconvened some members from the roadmap writing group as well as other experts, 
including several members of the Chagas Coalition, to write a follow-up paper exploring how COVID-19 
might impact people living with CD, and to provide preliminary guidance based on the limited amount of 
evidence available on the topic. The group consisted of several CD experts, some of whom have been on 
the front lines during the current crisis treating patients with COVID-19 or performing research on new 
treatments. The following document summarizes the consensus opinion of these experts on SARS-CoV-2/T. 
cruzi coinfection.
Pathophysiology of COVID-19 Infection in Relation to that of CD
CD is mainly transmitted through various species of hematophagous insects, although it can also be trans-
mitted transplacentally, through infected blood transfusions or organ donations, laboratory accidents, nee-
dle sharing among intravenous drug users (IVDU), and orally through food and drink contaminated with 
triatomines, their feces, or secretions from some host reservoir species. After infection and an incubation 
period of between 15 and 40 days, the acute phase of the disease generally lasts for one to two months and 
is followed by an indeterminate phase, when no clinical manifestations are observed. After decades in this 
silent state, roughly one-third of patients develop a chronic form of the disease characterized by organ dam-
age, mainly to the cardiovascular (CV) and gastrointestinal (GI) systems. The most serious sequelae of CD are 
stroke, sudden death from brady- or tachyarrhythmias, and congestive heart failure [1, 6].
COVID-19 interacts with the CV system on multiple levels. SARS-CoV-2 binds to the human angioten-
sin-converting enzyme 2 (ACE2) receptor mainly expressed in the lungs, heart, and vascular endothelium. 
Although analysis of the precise consequences is in its infancy, this interaction may trigger an inflamma-
tory response that, in turn, may lead to increasing myocardial injury and dysfunction [7, 8]. It is uncertain 
whether the altered immune state characteristic of COVID-19 disease can act as a potential trigger for CD 
progression, and how this might be influenced by both certain parasitic factors (type of strains, load of para-
sites) as well as host factors (genetic susceptibility and immune state, specifically IFN-Ɣ axis).
While parasitemia is low-level and evanescent in chronic CD, pharmacologic and disease-induced immu-
nosuppression risk reactivation of parasitemia [9, 10]; therefore, there is a concern that COVID-19 disease 
could potentially trigger reactivation of CD. This potential reactivation could be caused by an acquired 
hemophagocytic lymphohistiocytosis-like disease (cytokine storm), the virus itself, or even the use of 
some COVID-19 treatments such as steroids, hydroxychloroquine [5] and other immune-modulating drugs 
(i.e. tocilizumab or other interleukin inhibitors), as interleukins are related to the progression of CD [11, 12]. 
This may be influenced by certain parasitic factors or host factors.
Implications for chronic Chagas cardiomyopathy
The pathogenesis of chronic Chagas cardiomyopathy (CCC) involves a complex interaction between dif-
ferent processes related to tissue damage due to parasite persistence, inflammation, specific immune 
response, fibrosis, dysautonomia, and microvascular changes [13]. Chronic, persistent infection of the 
 1 http://www.coalicionchagas.org/en_GB/news-article/-/asset_publisher/hJnt8AyJM2Af/content/preguntas-y-respuestas-sobre-
covid-19-y-chagas).
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myocardium elicits an inflammatory response which, although necessary for the control of parasite 
proliferation, results in tissue damage leading to myocardial fibrosis and cardiac remodeling [14]. The 
pro-inflammatory response includes, but is not limited to, secretion of Th1 cytokines and chemokines, 
eicosanoids, and endothelin-1 [14].
Similar to the case for T. cruzi infection, direct damage to cardiac tissue also is possible with SARS-CoV-2, 
which binds to the ACE2 receptor to enter type 2 pneumocytes, macrophages, perivascular pericytes, and 
cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvas-
cular dysfunction, plaque instability, and myocardial infarction (MI) [15]. Initial immune and inflammatory 
responses induce a severe cytokine storm [16], including cytokines and chemokines frequently related to 
the inflammatory response implicated in the pathogenesis of CCC, such as interleukin (IL)-6, TNF-alpha, and 
CXCL10 [17, 18]. Indeed, COVID-19 related myocarditis cases have been reported and are thought to be a 
combination of direct viral injury and cardiac damage due to the host immune response [19].
Further depression of the ventricular function by COVID-19 could be caused by additional mecha-
nisms, such as myocardial infarction and microvascular dysfunction, also found in T. cruzi infection [15]. 
Furthermore, arrhythmia is recognized as one of the possible clinical manifestations of COVID-19 patients, 
thus COVID-19 could plausibly precipitate arrhythmias in patients with an arrhythmogenic substrate, such 
as CCC [19].
Finally, COVID-19 may predispose patients to thrombotic disease, both in the venous and arterial circula-
tions, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis [20]. There are 
reports of upregulated procoagulative activity in the plasma of chronic CD patients [21] and thromboem-
bolic manifestations are also more frequent in these patients with CCC [22], although it is not clear if this 
interaction has clinical relevance.
Implications for chronic indeterminate CD
While patients living with the indeterminate form of CD are usually outpatients without manifest symp-
toms, they still require ongoing surveillance and care, which has become increasingly difficult due to the 
pandemic. For instance, patients with chronic indeterminate CD need yearly follow-up for cardiac tests, 
as 2–5% progress to chronic symptomatic disease annually, and ultimately 30–40% develop  cardiac or GI 
complications [1]. They may also benefit from antiparasitic treatment, which, in the case of women of child-
bearing age, can interrupt congenital transmission [23, 24]. However, the 2-month course of treatment 
requires ongoing monitoring and laboratory testing due to the potential for side effects. This essential 
care for patients with chronic indeterminate CD is likely to be hampered by the pandemic, both because 
of the potential risk of SARS-CoV-2 infection from attending healthcare facilities for routine appointments 
(or the need to use public transportation to travel to and from appointments), and because of postpone-
ments or delays in routine care as healthcare personnel and resources are focused on COVID-19 cases.
Furthermore, if assessed with more sensitive technology, including echocardiography, Holter, and mag-
netic resonance with late gadolinium enhancement, a small number of indeterminate-phase patients may 
be reclassified as having CCC due to the presence of areas of fibrosis with wall motion abnormalities [25–30]. 
Therefore, an unknown proportion of individuals classified as being in the indeterminate phase may indeed 
develop arrhythmias or other cardiovascular complications if challenged with a cytokine storm such as that 
triggered by COVID-19.
Implications for gastrointestinal and neurological forms of CD
Atypical chest pain, abdominal pain, and nausea are nonspecific symptoms related to upper digestive CD 
involvement, and all three have been related to COVID-19 pulmonary and extrapulmonary clinical pres-
entation [31, 32]. However, constipation is the main symptom of lower digestive tract involvement due 
to T. cruzi infection which is the opposite of diarrhea, the main GI symptom observed in extrapulmonary 
forms of COVID-19. The presence of GI symptoms, widely described in COVID-19 case series and present in 
3–11.6% of patients with COVID-19 [31], has been associated with high ACE2 expression in the GI tract that 
could indicate the potential of virus mutation towards increased transmissibility, decreased virulence, and 
multiorgan infection [31]. When GI symptoms that occur in both diseases are noted in an individual in an 
area of high SARS-CoV-2 transmission, etiological consideration must be given to either CD progression or 
COVID-19, considering the implications in terms of mutation and transmissibility.
There is increasing evidence that coronaviruses are associated with neurological disorders [33]. Studies 
on severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) suggest 
that coronaviruses are neurotropic. A systematic review of the literature until April 2020 associated mul-
tiple neurological disorders with COVID-19, including encephalitis, demyelination, and neuropathy [34]. 
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COVID-19 could potentially induce the development of chagasic neuropathy, which is sometimes observed 
in chronic CD.
Congenital cases
Maternal-fetal transmission of T. cruzi occurs in an average of 5% of pregnancies of mothers with chronic 
CD [35]. Parasite load is a key determinant of congenital transmission [36]. The immunological response 
to COVID-19 is extensive, and its impact on T. cruzi parasitic load is unknown. Should it be found that 
COVID-19 increased parasitemia in pregnant women with CD, it could increase the likelihood of mater-
nal-fetal transmission. Screening of infants born to T. cruzi-infected mothers remains crucial and could 
 potentially be disrupted by the negative impact of COVID-19 on access to care [37, 38].
Immunosuppressed patients
Immunosuppressed patients are at increased risk of severe COVID-19, especially those with aggressive 
underlying disease, active immunosuppressive treatment, or lymphopenia. Overproduction of cytokines 
during COVID-19 infection leads to significant tissular damage, particularly in the lungs. This intense COVID-
19 inflammatory process in immunosuppressed CD patients could influence the evolution of disease and 
potentially trigger CD reactivation, due either to viral infection interference, such as seen in HIV infection 
[39], or to possible immunosuppressive therapy for COVID-19 [9, 10] and is associated with the severity of 
underlying diseases. Conversely, any approach that improves the immune response at this level is desirable, 
either using antiviral or cytokine blocking agents (IL-6, IL-1β, TNF-a) [40]. On the other hand, there is the 
risk of inducing clinical activation of autoimmune disease in individuals with asymptomatic COVID-19 and, 
consequently, a potential reactivation of CD [41].
Epidemiological Considerations
The spread of the COVID-19 pandemic in countries affected by CD raises concerns for several reasons. The 
population with T. cruzi infection, which numbers over six million people worldwide [3, 42], is aging, at 
risk of CCC, has a significant burden of comorbidities, and is socioeconomically vulnerable. All these factors 
could potentially increase the impact of COVID-19 in this population, especially within a scenario of weak-
ened and overloaded health systems.
In most countries where CD transmission has been controlled or reduced, CD patients are becoming older 
and suffer from comorbid conditions [43]. Further investigation is needed to fully understand the impact of 
comorbid illnesses in CD patients, including the role of immunosuppressive conditions arising from CD or 
from CD therapies. In addition to age, many chronic medical conditions, such as diabetes, COPD and other 
cardiovascular diseases are also known risk factors for COVID-19 mortality. Moreover, elderly CCC patients 
have higher risk of death than age-matched seronegative individuals [43]. It is likely, therefore, that CCC, in 
part because of its association with age and other chronic conditions, along with the challenging socioeco-
nomic context affecting many people with CD, would further increase the risks of severe COVID-19 infection.
Although the incidence of new CD infections is around 30,000 annually [3], this number has declined in 
recent decades, meaning a high proportion of people living with CD are older or aging [44]. While >80% 
of COVID-19 cases are mild or asymptomatic, severe cases are more common among older adults. In a ret-
rospective study, the risk of mortality increased by 1.03–1.17% with every year of increased age in patients 
from Wuhan [45]. Another study using data from various countries estimated a case fatality ratio of 4.5% 
in individuals older than 60, compared to 1.4% in those younger than 60, with the highest rates in patients 
over 80 [46]. In the United States, 78.6% of deaths have occurred in people 65 or older [47].
Over one million people in the Americas suffer from CCC [3], and underlying cardiovascular disease is a 
major risk factor for hospitalization and death from COVID-19. The incidence of acute cardiac injury from 
COVID-19 has been reported as 8% in hospitalized patients (48), and (in one Chinese study) was much more 
prevalent in deceased (59%) than recovering patients (1%) [49]. Cardiovascular disease was also identified 
in 30% of COVID-19 related deaths in Italy [50], while age > 60 and Charlson Comorbidity Index > 3 were 
associated with greater mortality in a U.S. cohort of 1305 hospitalized patients [51].
Finally, several studies have noted high levels of comorbidities among both patients with CD and those 
with severe forms of COVID-19. One Brazilian study identified a mean of 2.7 chronic comorbidities in CD 
patients [52]. In 168 CD patients in São Paulo, 51.2% had hypertension and 23.8% had diabetes mellitus 
[53]. Another study in a younger sample of 137 patients in Switzerland found 2.9% had diabetes and 17% 
had hypertension [54]. Both hypertension and diabetes were associated with high mortality rates from 
COVID-19 in China (7.3% and 6.0% respectively) [55], and were 2–3 times more prevalent in severe vs. 
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non-severe hospitalizations [48]. Diabetes was also prevalent in a third of deaths in an analysis of Italian 
COVID-19 data [56]. It is important to note that these comorbidities also reflect the older age of the popula-
tions which are especially impacted by both CD and COVID-19.
Social Context and Access to Healthcare
As the pandemic progresses from Europe and the United States into the Global South, it is increasingly 
impacting vulnerable populations. In the U.S., COVID-19 has thus far had a greater impact on Blacks and 
Latinos. According to the CDC, these groups have a higher prevalence of infection and higher weighted 
distribution of deaths than expected from their distribution in the general population [57]. A higher rate of 
deaths among people in Brazil who self-identify as black has also been reported [58, 59]. These racial dispari-
ties are, in turn, framed by historically rooted socioeconomic considerations which often determine who is 
able to self-isolate and avoid exposure.
Moreover, social vulnerability has long been documented in people with CD [60], and groups with high 
burdens of CD, including indigenous people, the rural poor, and migrants may face particular challenges in 
accessing healthcare. People living at or near the poverty level are also especially vulnerable to the economic 
impact of the pandemic, as experts have warned that years of gains in reducing poverty are now in jeopardy. 
The UN predicts that a global GDP shrinkage of 3.2% in 2020, will push 34 million more people into extreme 
poverty [61]. The worsening economic situation threatens to make access to healthcare even more precarious 
for people living with CD, who are often forced to make difficult decisions between spending time and 
money on healthcare or on other pressing priorities. Many work in the informal sector or in positions that 
do not offer paid time off or health insurance.
People with CD may feel more reluctant to seek care in a clinic for fear of exposure to COVID-19, and may, 
therefore, put off addressing complications related to CD. Indeed, there have been reports of low utiliza-
tion of services and delayed presentation for chronic conditions since the onset of the pandemic [62, 63]. 
Finally, CD can create a significant emotional burden for affected people who worry about the progression 
of the disease, and the pandemic may make it harder to access both mental health services and traditional 
support networks of families and friends. Patients with CD who acquire COVID-19 may experience particular 
concern and anxiety. As COVID-19 becomes a part of daily reality, creative responses will be needed from 
patient groups, social workers, mental health practitioners, and others to continue providing support to 
people with CD.
Recommendations for Healthcare Providers
Screening/testing of Chagas disease during the pandemic
While the indications for screening and diagnosing CD are unchanged during the COVID-19 pandemic, 
the timing of testing depends on the degree to which the diagnosis of CD will affect short term man-
agement of the individual being tested. Urgent testing remains appropriate for pregnant women, 
infants born to seropositive mothers, and any individual about to receive immunosuppression. Screen-
ing of blood donations also remains critical. Patients presenting with clinical syndromes suggestive 
of CD should also receive urgent testing to guide evaluation and therapy. Pregnant women from CD-
endemic countries should also be screened to evaluate for the possibility of maternal-fetal transmis-
sion. Depending on the circulation of SARS-CoV-2 in the community and local guidelines, widespread 
screening of individuals without symptoms from endemic countries could be postponed until it can be 
performed safely, with the understanding that while antiparasitic therapy may be indicated, it can gener-
ally be delayed until the patient can report for lab testing and follow-up visits without significant risk 
of exposure.
Management of patients coinfected with Chagas disease and COVID-19
Below, preliminary recommendations are provided for patients with CD who acquire COVID-19. The recom-
mendations are divided depending on the patient’s form of CD.
Acute forms of CD
Acute cases of CD following congenital, vector, or oral transmission, as well as those via transfusion, labora-
tory accidents, and other routes generally warrant antiparasitic treatment as early as possible, even in the 
context of the COVID-19 pandemic. If the patient is coinfected with COVID-19 and the acute form of CD, 
timely antiparasitic treatment of CD is needed, but clinicians should be mindful of the severity of COVID-19 
symptoms.
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Congenital CD
Cases of congenital transmission are acute cases of CD, and treatment is effective with few side effects. 
COVID-19 is generally not severe in infants and children [64]. If the child does not have COVID-19 symptoms, 
antiparasitic treatment should be given as soon as the diagnosis of T. cruzi infection is  established [37].
Reactivation
Patients must be admitted to the hospital and receive antiparasitic treatment with benznidazole for 60 
days. However, if a full 60 days of treatment is not possible because of adverse events, treatment should 
still be continued for as close to 60 days as possible using anti-histaminic and/or anti-inflammatory drugs. 
Reactivation involving myocarditis/meningoencephalitis is of particular concern due to the occurrence of 
vascular/nervous system/myocardium involvement by COVID-19 and should be carefully monitored in an 
intensive care unit.
Immunosuppression without reactivation
In this case, antiparasitic treatment could be delayed until the patient can safely attend a clinic, depending 
on self-isolation guidelines and the risk of exposure to COVID-19. However, CD reactivation with signs in 
target organs should be closely monitored by clinical follow-up, direct microscopy (concentration methods) 
on peripheral blood and/or secretions [39], and, if possible, quantitative PCR during COVID-19 infection 
according to local protocols.
Indeterminate chronic CD
From an individual health management point of view, people with asymptomatic infection (in the inde-
terminate clinical form of CD) are those in whom there is evidence of T. cruzi infection, but no evidence 
of organ damage (mainly cardiovascular or digestive), assessed by non-specific symptoms and low sen-
sitivity tests to detect early organ damage, such as electrocardiogram, chest X-ray, and barium  swallow 
and enema [65]. With or without antiparasitic treatment, regular monitoring is recommended to eval-
uate the clinical condition during follow-up and to quickly detect treatment failure and/or clinical 
progression.
As a general recommendation, and given the current epidemiological situation, it is important to assess 
the risk-benefit of referring a patient to a healthcare center. It is essential to preserve patient safety in terms 
of preventing new cases of COVID-19. However, it is also important from a public health perspective to 
optimize existing resources for health care. Outpatient visits as well as regular cardiovascular and gastroin-
testinal tests could be delayed if CD patients are stable. The use of telehealth tools for virtual consultation 
is highly recommended, including incorporating advice to patients about the need to contact healthcare 
facilities in case of the onset of symptoms, either from CD or possible COVID-19 infection.
Etiological treatment of Chagas disease
Etiological (antiparasitic) treatment in patients with CD without evidence of organ involvement is recom-
mended for acute cases and most chronic cases in the indeterminate form or with only mild cardiomyopathy 
[5, 66]. In the current context of the pandemic, however, two main aspects should be considered: 1) drug 
characteristics and potential interactions with current treatment of COVID-19, and 2) the urgency of the 
indication for anti-T. cruzi drugs.
Drug characteristics
Benznidazole (BZN) and nifurtimox (NFX) are the two drugs accepted by regulatory agencies for antipara-
sitic treatment of CD. BZN (N-benzyl-2-nitro-1-imidazole acetamide) is a nitroimidazole that inhibits DNA, 
RNA, and protein synthesis of T. cruzi. NFX (5-nitrofuran 3-methyl-4-(5’-nitrofurfurylideneamine) tetrahy-
dro-4H-1,4-tiazine-1,1-dioxide) is a nitrofuran derivative whose mechanism of action involves various reduc-
tion and oxidation reactions of its nitro constituent, leading to the production by parasite enzymes of a 
variety of reactive oxygen species that react with cellular macromolecules and are lethal to the parasite. NFX 
also leads to the inactivation of a critical trypanosomal enzyme, trypanothione reductase [67].
In both cases, the mechanism of action is not completely described, and exploration of the potential inter-
actions between BZN and NFX with most common drugs used in COVID-19 management should be taken 
into consideration and further explored. Due to the hepatic metabolism of BZN (95%) and NFX (>99%), 
hepatotoxicity in combination with anti-COVID-19 drugs must be monitored.
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Treatment indications and follow-up of patients under treatment
Etiological treatment of T. cruzi infection is an emergency only under very specific circumstances [68]. Even 
if adverse drug reactions (ADRs) related to BZN and NFX are non-severe in most cases [69], close follow-up 
of patients who start a BZN or NFX regime is recommended to identify side effects promptly and to moni-
tor hepatic and hematologic function [54, 70, 71]. During the pandemic, delaying initiation of etiological 
treatment regimens for chronic T. cruzi infection without organ involvement is a valid course of action in 
healthcare settings, to avoid unnecessary exposure to COVID-19 and because of limitations in follow-up 
due to decreased in-person care. Nevertheless, patients diagnosed with COVID-19 may receive immunosup-
pressive therapy, and close monitoring to diagnose CD reactivation early in its course is recommended. In 
the case of clinical and/or parasitological evidence of reactivation, starting treatment with BZN or NFX is 
considered an emergency [68].
If a patient is already receiving BZN or NFX, treatment should be continued, and self-quarantine measures 
to avoid COVID-19 should be taken. Telehealth tools for treatment follow-up are recommended as well as 
minimization of contact with healthcare facilities, which would primarily only be indicated to perform labo-
ratory tests usually recommended during treatment to monitor hepatotoxicity and hemogram alterations 
due to BZN or NFX, or in the event of concerning ADRs. If a patient under treatment with BZN or NFX devel-
ops symptomatic COVID-19 infection providers could consider on a case-by-case basis whether to interrupt 
treatment, depending on the severity of symptoms and the type of treatment required. There is no evidence 
of drug-drug interaction between antiparasitics for CD and the drugs currently under investigation to treat 
COVID-19; treatment of CD in the indeterminate form is non-urgent.
Table 1 summarizes guidance for providing etiological treatment of CD during the pandemic, taking into 
account both the patient’s form of CD and their COVID-19 status.
In all cases, etiological treatment of Chagas disease should be accompanied by appropriate close follow-
up, including liver enzymes and blood count parameters. See Echeverria et al. 2020 [68].
Management of patients with Chagas cardiomyopathy and COVID-19
COVID-19 has been associated with multiple cardiac manifestations that include cardiac arrhythmias, Type 2 
and 1 myocardial infarction, heart failure exacerbations and acute fulminant myocarditis [72, 73]. Potential 
interactions between COVID-19 and CCC may be expected primarily due to the common immunological 
Table 1: Etiological treatment recommendations for Chagas disease in the context of COVID-19 coinfection.*
Chagas disease status COVID-19 status Guidance for etiological treatment with benznidazole 
or nifurtimox
Chronic, indeterminate Negative Consider delaying treatment to minimize risk of COVID-19  exposure 
based on local epidemiological context and current physical 
 distancing regulations.
Chronic, indeterminate Positive, with or 
without symptoms
Consider delaying treatment until COVID-19 is completely resolved 
and based on local epidemiological context and current physical 
distancing regulations.
Acute cases Negative or 




or  parasitological 
 evidence of reactivation
Negative or posi-








Postpone treatment; if immunosuppressive drugs are prescribed in 
the context of COVID-19 management, closely monitor for reactiva-
tion of T. cruzi infection by direct microscopy on peripheral blood or 
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pathways shared by the diseases, as angiotensin-converting enzyme 2 (ACE2) is involved in heart function 
and the development of hypertension and diabetes mellitus, risk factors frequently observed in patients 
with CCC. ACE2 levels can be increased by the use of ACE inhibitors and/or angiotensin receptor blockers 
(ARBs) which are frequently used for the management of CCC. There is no evidence to date to support dis-
continuation of either ACE inhibitors or ARBs based on the theoretical potential of increasing the suscepti-
bility to COVID-19 infection. Most cardiovascular societies including ESC, ACC, AHA, CCS, and the IASC have 
indicated that these medications should be continued regardless of the presence of concomitant COVID-19 
manifestations. This should also be the case for patients with CCC.
Other potential interactions may occur in patients with CCC currently treated for cardiac arrhythmias, 
such as atrial fibrillation or life-threatening ventricular arrhythmias receiving amiodarone, as the potential 
for increased QT interval with treatments that have been proposed for COVID-19 such as hydroxychloro-
quine and/or azithromycin may increase the risk of torsade de points.
Patients with CCC must continue their usual treatments during the COVID-19 pandemic. Outpatient 
clinics may use telehealth, if available, to avoid putting these vulnerable patients at risk of SARS-CoV-2 infec-
tion. With proper hygiene and self-care measures, cardiac tests like EKG, echo, stress tests, or Holter may be 
performed or slightly delayed, always weighing risk-benefit and regional SARS-CoV-2 circulation status. If a 
patient with CCC develops new arrhythmias, stroke, or acute or worsening chronic heart failure, hospitaliza-
tion must not be delayed. As hospitals in some regions may be severely strained by COVID-19, care of these 
acute events may be compromised, putting CCC patients at risk.
Table 2 lists potential interactions between cardiovascular drugs used to treat CCC and some proposed 
COVID-19 treatments.
Table 2: Potential interactions between COVID-19 treatments under investigation and CCM drugs.
COVID-19 treatments under investigation Potential interactions with CCM drugs
Chloroquine-hydroxychloroquine Inhibits CYP2D6 (increasing half-life of most of the beta blockers 
[74] and amiodarone), and inhibits and downregulates PgP [75]. 
They do not interact with novel oral anticoagulants (NOACS) or 
vitamin K antagonists (VKAs) [76].
Protease inhibitors (lopinavir-ritonavir) By inhibiting CYP3A4, they increase plasma levels of most of CV 
drugs. May lower the effect of VKAs by induction of CYP2C19 and 
increase plasma levels of NOACs. Also may increase amiodarone 
levels [77]. 
Azithromycin Increases levels of warfarin/acenocoumarol, these anticoagulants 
should be withdrawn during azithromycin treatment. Due to PgP 
inhibition, dose reduction of NOACs may be required.
Atazanavir Increases levels of VKAs and NOACs (should be discontinued). May 
increase amiodarone levels and effect. May increase digoxin levels. 
Mild increase in atenolol levels (beta blocker) [77].
Remdesivir No relevant interactions.
Favipiravir, Bevacizumab, Ecolizumab, 
Fingolimod, Pirfenidone, Interferon 
 Methylprednisone
No relevant interactions.
Tocilizumab May lower effect of anticoagulants.
Nitazoxanide May increase VKA levels; do not use concomitantly.
Sarilumab It is a CYP3A4 inducer, but dose modifications are not 
 recommended.
Interferon and Methylprednisolone Reduction of VKAs is advised.
Ribavirin Interferes with the absorption of VKAs, possible dose increase 
 indicated. Enalapril and other ACE2 inhibitors may provoke dry 
cough as well as ribavirin [78]. 
Ivermectin May decrease the effect of warfarin and dicoumarol. Risk of 
 myopathy with captopril [79].
(Contd.)
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Future needs
Our current understanding of the potential interrelations between CD and COVID-19 is still limited; there 
are substantial needs for future research. The recommendations provided in this document should be con-
sidered preliminary and may require refinement and adjustment as our understanding of both diseases 
develops. Table 3 lists some of the most important gaps in our current clinical knowledge. Research from 
other disciplines will also be needed to better understand the epidemiology of both diseases, the social and 
psychological impacts of the pandemic on people with CD, new access barriers that emerge in the context of 
the pandemic and the economic dislocation it causes, and the particular contexts of vulnerable populations 
including migrants and indigenous communities.
Conclusion
While global in scope and indiscriminate in whom it infects, COVID-19 poses a particular risk to people 
with CD. Both diseases are more prevalent in marginalized populations, whose access to appropriate care 
is limited, and whose exposure to risk factors is proportionally higher. COVID-19 is more lethal in indi-
COVID-19 treatments under investigation Potential interactions with CCM drugs
Oseltamivir No CYP interactions with CV drugs. However, case reports and series 
show some increase in the effect of VKAs [75].
Arbidol (Umifenovir) May decrease metabolism of labetalol (beta-blocker) [80].
Canakinumab No known drug interactions, but upregulation of CYP enzymes may 
further modify metabolization of CV drugs [81, 82].
Anakinra No drug interactions.
Emapalumab No known drug interactions, but upregulation of CYP enzymes may 
further modify metabolization of CV drugs [83].
Siltuximab VKA interaction through CYP3450. Close monitoring [84]. 
Cyclosporin A Cyclosporin may increase digoxin levels. Amiodarone, losartan, 
and valsartan increase cyclosporin levels; ACE inhibitors increase 
nephrotoxicity [85, 86]. 
Sirolimus Serious warning; may increase risk of ACE inhibitor related angi-
oedema. CYP450 and PgP interactions [87].
Darunavir/cobicistat Drugs metabolized by CYP3A4, CYP2D6, or that use the transporters 
PgP, BCRP, MATE1, OATP1B1 or OATP1B3 may have interactions [88].
Anticoagulants, beta blockers, and digoxin should be used with 
caution.
Table 3: Understanding the interactions between COVID-19 and CD: Gaps and needs.
Disease interaction Clinical questions Drug development needs
•	 How is the natural history of CD 
affected by COVID-19?
•	 Can the cytokine storm trigger 
reactivation of parasitemia?
•	 Does the cytokine storm trigger 
disease progression?
•	 Do viral and parasitic immune 
response pathways cross react?
•	 Does the chronic inflammatory 
state of CD lead to more severe 
COVID-19 disease?
•	 Does the prothrombotic state 
from both diseases behave 
 synergistically?
•	 What precautions are necessary 
regarding COVID-19 treatment in 
CD patients?
•	 What are the hemodynamic and 
arrhythmic risks of COVID-19 in 
patients with CCC?
•	 What is the impact of delaying 
CD treatments during COVID-19 
infection?
•	 What is the impact of delays 
in access to CD diagnosis and 
 cardiac evaluation?
•	 What is the impact of possible 
health system collapse on qual-
ity of care of CD patients with 
 symptomatic disease? 
•	 What are the antiviral effects 
of antiparasitic drugs for CD 
(BZN and NFX)?
•	 Can anti-inflammatory drugs 
improve host response to COVID-
19 and complement antiparasitic 
 treatment of CD?
•	 Can allopurinol or colchicine help 
delay or avoid  complications for 
both diseases?
•	 Is full anticoagulant therapy useful 
for COVID-19 [89] and CD [90]?
•	 Could CV CD treatments such as 
amiodarone treat COVID-19?
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viduals with cardiac disease and/or other cardiac risk factors, such as diabetes and obesity, which are also 
prevalent in individuals with CD. The mechanisms of COVID-19 disease, while not completely understood, 
theoretically pose a risk of both exacerbation of cardiac dysfunction from CD and acute reactivation of 
CD due either to disease-induced immunomodulation or therapeutic immunosuppression. The economic 
impact of the pandemic hits hardest in the lowest socioeconomic strata, further complicating the ability 
of many individuals with CD to obtain the treatment they need for either illness. Efforts to mitigate the 
spread of COVID-19, by limiting medical facilities to all but the most urgent care, complicates efforts to 
diagnose, treat, and monitor patients with CD, which may lead to clinical deterioration, increased mater-
nal-fetal transmission, and underdiagnosis, all of which were significant concerns even before the onset 
of the pandemic.
Roadblocks to accessing proper care for CD were recently described in the WHF-IASC Roadmap on CD [5]. 
Using a similar framework, Table 4 assesses the potential effect of the pandemic on key roadblocks to CD 
healthcare.
The end of the pandemic in Latin America is still far from sight and its full impact on healthcare and 
healthcare access, in particular, remains to be seen. CD has long been a hidden disease, with low awareness 
among healthcare professionals and people at risk, and limited commitment from governments. In the 
short-term, as public health resources are intently focused on mitigating the pandemic, it could become 
even more of a challenge to raise awareness of CD. At the same time, the pandemic could serve as an oppor-
tunity to strengthen public concern for addressing comorbid conditions and meeting the healthcare needs 
of underserved populations. Still, the current reality requires us to rethink traditional approaches to CD 
and other neglected diseases, to ensure we continue to make progress toward their eradication even as new 
public health challenges emerge. Ultimately, neither CD nor COVID-19 can be separated from their socioeco-
nomic context, and winning the struggle against both diseases will involve implementing comprehensive 
programs that focus on strengthening the healthcare rights and access of the marginalized people who are 
currently most impacted.
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